Neuromyelitis Optica Spectrum Disorder Market Report 2026

The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.54 billion in 2025 to $2.76 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to increasing awareness of nmosd, early development of immunosuppressive treatments, initial use of corticosteroids for flare control, adoption of imaging for differential diagnosis, rising identification of aqp4 antibodies.

The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.76 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing demand for targeted biologics, increasing development of mog-antibody therapies, expansion of advanced diagnostic platforms, rising investment in autoimmune research, development of next-generation immunotherapy solutions. Major trends in the forecast period include increasing adoption of monoclonal antibody therapies, rising use of advanced imaging techniques for early diagnosis, growing demand for plasma exchange and immunoglobulin therapy, expansion of aqp4-positive and mog-antibody testing, increasing focus on relapse prevention and long-term disease management.

The rising prevalence of multiple sclerosis is expected to drive the growth of the neuromyelitis optica spectrum disorder market in the coming years. Multiple sclerosis is a chronic autoimmune condition that affects the central nervous system, leading to inflammation, nerve damage, and a range of neurological symptoms. The growing incidence of multiple sclerosis is attributed to improvements in diagnostic technologies, environmental factors, and genetic susceptibility. Advances in medical imaging techniques, particularly MRI, have enabled earlier and more accurate diagnosis, contributing to the apparent increase in reported cases. As more individuals are diagnosed with multiple sclerosis, awareness of autoimmune neurological disorders has increased, resulting in improved diagnostic practices and greater recognition of neuromyelitis optica spectrum disorder. For example, in May 2024, the Multiple Sclerosis Trust, a UK-based national charity, reported that approximately 7,100 new multiple sclerosis cases are diagnosed annually in the UK, with around 135 individuals diagnosed each week. Consequently, the increasing prevalence of multiple sclerosis is fueling the growth of the neuromyelitis optica spectrum disorder market.

Major companies operating in the neuromyelitis optica spectrum disorder market are concentrating on the development of innovative therapies, such as long-acting complement inhibitors, to improve treatment effectiveness and patient outcomes. Long-acting complement inhibitors are therapies designed to suppress the complement system over extended periods, thereby reducing inflammation and preventing nerve damage in neuromyelitis optica spectrum disorder. These treatments help lower relapse rates and support sustained disease management. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical company, in collaboration with AstraZeneca, a UK-based pharmaceutical company, received approval for ULTOMIRIS (ravulizumab-cwvz) for treating adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder. This approval established Ultomiris as the first and only long-acting C5 complement inhibitor available for NMOSD treatment. The decision was supported by results from the Phase III CHAMPION-NMOSD trial, in which Ultomiris demonstrated a 98.6% reduction in relapse risk over 73 weeks compared with placebo, with no relapses observed among trial participants and no new safety concerns reported.

In October 2023, Amgen, a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen expanded its presence in the rare and autoimmune disease market, strengthening its portfolio with first-in-class therapies such as UPLIZNA for adult patients with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder. Horizon Therapeutics plc is an Ireland-based biotechnology company specializing in treatments for neuromyelitis optica spectrum disorder.

Major companies operating in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd, Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc, Oregon Health & Science University, Arup Laboratories, Argenx SE, Metropolis Healthcare, Rush University Medical Center, Mitsubishi Tanabe Pharma Corporation, Viela Bio, Alexion Pharmaceuticals, Horizon Therapeutics plc, UCB S.A, Teva Pharmaceutical Industries Ltd, Novartis AG, Sanofi S.A, Pfizer Inc, Eli Lilly and Company, Immune Pharmaceuticals Inc.

North America was the largest region in the neuromyelitis optica spectrum disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromyelitis optica spectrum disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuromyelitis optica spectrum disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the NMOSD market by increasing the costs of importing biologics, diagnostic reagents, and advanced imaging equipment required for accurate detection and treatment. These tariffs significantly affect hospitals, specialty clinics, and homecare providers in regions reliant on imported therapies such as Europe and Asia-Pacific, leading to higher treatment costs and slower distribution of monoclonal antibodies and plasma exchange systems. Diagnosis segments involving MRI and blood testing face procurement delays and increased operational expenses. Nevertheless, tariffs are prompting growth in domestic pharmaceutical production, supply chain resilience, and regional development of lower-cost immunotherapy alternatives.

The neuromyelitis optica spectrum disorder market research report is one of a series of new reports that provides neuromyelitis optica spectrum disorder market statistics, including neuromyelitis optica spectrum disorder industry global market size, regional shares, competitors with a neuromyelitis optica spectrum disorder market share, detailed neuromyelitis optica spectrum disorder market segments, market trends and opportunities, and any further data you may need to thrive in the neuromyelitis optica spectrum disorder industry. This neuromyelitis optica spectrum disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition that affects the central nervous system, mainly involving the spinal cord and optic nerves. It is marked by intense inflammation and demyelination, which is damage to the protective covering of nerve fibers, resulting in symptoms such as vision impairment, paralysis, and sensory loss.

The primary types of neuromyelitis optica spectrum disorder include NMOSD with aquaporin-4 antibodies and NMOSD without aquaporin-4 antibodies. NMOSD with aquaporin-4 antibodies occurs when the immune system attacks nerve fibers, leading to inflammation, vision loss, and paralysis. Diagnosis is carried out using several methods, including imaging tests, magnetic resonance imaging (MRI), blood tests, and others, while treatment options include C5 protein inhibitors, monoclonal antibodies, plasma exchange therapy, corticosteroids, immunoglobulin therapy, medications, and other approaches. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used by various end-users, such as hospitals, specialty clinics, home care settings, and other healthcare facilities.

The neuromyelitis optica spectrum disorder market consists of revenues earned by entities by providing services such as rehabilitation services, patient assistance programs, and intravenous immunoglobulin (IVIG) therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuromyelitis optica spectrum disorder market includes sales of immunosuppressants, corticosteroids, and symptomatic treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.